Transferrin-targeted magnetic/fluorescence micelles as a specific bi-functional nanoprobe for imaging liver tumor

Qi, Hui; Li, Zhengzheng; Du, Kai; Mu, Ketao; Zhou, Qing; Liang, Shuyan; Zhu, Wenzhen; Yang, Xiangliang; Zhu, Yanhong

doi:10.1186/1556-276x-9-595

Cited by 16 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jin et al reported a bifunctional probe for targeting and imaging liver cancer, but this was only achieved in vitro [20]. In addition, Hui et al only achieved dual-modality imaging in heterotopic liver tumors [21]. …”

Section: Discussionmentioning

confidence: 99%

Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes

et al. 2017

View full text Add to dashboard Cite

The accurate preoperative detection and intraoperative navigation afforded by imaging techniques have had significant impact on the success of liver cancer surgeries. However, it is difficult to achieve satisfactory performance in both diagnosis and surgical treatment processes using any single modality imaging method. Here, we report the synthesis and characteristics of a novel dual-modality magnetic resonance imaging (MRI) and near-infrared fluorescence (NIRF) probe and verify its feasibility in nude mouse models with liver cancer. The probes are comprised of superparamagnetic iron oxide (SPIO) nanoparticles coated with liposomes to which a tumor-targeted agent, Arg-Gly-Asp peptides (RGD), and a NIRF dye (indocyanine green, ICG) have been conjugated. Specific targeting, biodistribution, and the imaging ability of the probes for MRI-NIRF were examined. Furthermore, we applied the dual-modality methodology toward the preoperative diagnosis and intraoperative guidance of radical resection in mouse models with both orthotopic liver tumors and intrahepatic tumor metastasis. The study demonstrated that both MRI and fluorescent images showed clear tumor delineation after probe injection (SPIO@Liposome-ICG-RGD). The contrast-to-noise ratio obtained from MRI was 31.9 ± 25.4 at post-injection for the preoperative diagnosis, which is helpful for detecting small tumors (0.9 ± 0.5 mm). The maximum tumor to background ratio of NIRF imaging was 2.5 ± 0.3 at 72 h post-injection for effectively capturing miniscule tumor lesions (0.6 ± 0.3 mm) intraoperatively. The novel MRI-NIRF dual modality probes are promising for the achievement of more accurate liver tumor detection and resection.

show abstract

Section: Discussionmentioning

confidence: 99%

Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The study demonstrated that SPPTC offered outstanding targeting on the MRI and uorescence imaging. 191 Yan et al studied targeting specicity of the anti-a v b 3 antibody through molecular MRI imaging. 192 They fabricated a PEG modied Fe 3 O 4 core.…”

Section: Metal Oxide-based Cancer Diagnostics and Imaging Technologie...mentioning

confidence: 99%

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics

Subhan

2022

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…In order to achieve liver tumor imaging with bi‐functional nanoprobes, Qi et al117 encapsulated SPIONs into PEG‐poly(ε‐caprolactone) (PEG‐ b ‐PCL) polymeric micelles, that were then decorated with Tf and the NIR fluorescent dye Cy5.5 to produce nanosized SPIO@PEG‐ b ‐PCL‐Tf/Cy5.5 (SPPTC). No expression of TfR mRNA in the HL7702 normal cell line was observed, while there was good expression in the HePG2 carcinoma cells.…”

Section: Cancer Cell Surface Marker Targetingmentioning

confidence: 99%

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

Azizi

Dianat‐Moghadam

Salehi

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Although considerable efforts have been conducted to diagnose, improve, and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. Perhaps the best hope for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase the current understanding of tumor biology, and will allow nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Owing to their intrinsic physicochemical characteristics, nanostructures (NSs) are valuable tools that have received much attention in nanoimaging. Consequently, rationally designed NSs have been successfully employed in cancer imaging for targeting cancer-specific or cancer-associated molecules and pathways. This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membranecoated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology-based imaging probes in the future.

show abstract

Transferrin-targeted magnetic/fluorescence micelles as a specific bi-functional nanoprobe for imaging liver tumor

Cited by 16 publications

References 30 publications

Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes

Theranostic imaging of liver cancer using targeted optical/MRI dual-modal probes

Advances with metal oxide-based nanoparticles as MDR metastatic breast cancer therapeutics and diagnostics

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

Contact Info

Product

Resources

About